Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
This study includes a screening period of up to 35 days, a 16-week double-blind treatment period (Period A), and a 36-week double-blind treatment period (Period B).
Participants who meet eligibility criteria will be randomized at Baseline in a 2:2:1 ratio to one of 3 treatment groups: (1) risankizumab 150 mg, (2) risankizumab 300 mg, or (3) matching placebo. Randomization will be stratified by Baseline disease severity (Validated Investigator Global Assessment scale for Atopic Dermatitis \[vIGA-AD\] score of moderate \[3\] versus severe \[4\]) and geographic region (Japan versus rest of world).
At Week 16, participants in the placebo group will be re-randomized in a 1:1 ratio to receive either risankizumab 150 mg or 300 mg for the remainder of the study. Participants originally randomized to the risankizumab 150 mg or 300 mg arms will stay on their previously-assigned treatment through the end of the study.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adults who are ≥ 18 years old and, where locally permissible and approved, adolescent subjects who are at least 12 years old
a diagnosis of atopic dermatitis (AD) with onset of symptoms at least 2 years prior to Baseline and subject meets Hanifin and Rajka criteria
moderate to severe AD at the Baseline Visit
history of inadequate response to previous topical corticosteroid and/or topical calcineurin inhibitor treatments or a medical inability to receive these treatments
You may not be if
prior exposure to any biologic immunomodulatory agent or Janus kinase (JAK) inhibitor
concurrent treatment with systemic therapy for AD (biologic or non-biologic) or topical and/or phototherapy treatments